Review article: the current pharmacological therapies for hepatic encephalopathy

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2007-01-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1746-6342.2006.03218.xPMID 17295849
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hospitalizations During the Use of Rifaximin Versus Lactulose for the Treatment of Hepatic Encephalopathy

  2007cited by this paper
• Effects of L-carnitine in patients with hepatic encephalopathy.

  2005cited by this paper
• Rifaximin: a novel antimicrobial for enteric infections

  2005cited by this paper
• A randomized controlled trial of acarbose in hepatic encephalopathy.

  2005cited by this paper
• Rifaximin: A New Treatment for Travelers' Diarrhea

  2005cited by this paper
• Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study

  2005cited by this paper
• Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

  2004cited by this paper
• 204 Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review of randomised trials

  2004cited by this paper
• Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study.

  2004cited by this paper
• Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study.

  2003cited by this paper
• The neurology of liver failure.

  2003cited by this paper
• Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

  2003influential reference
• Treatment of hepatic encephalopathy.

  2001influential reference
• Hepatic encephalopathy. Metabolic consequence of cirrhosis often is reversible.

  2001cited by this paper
• Hepatic encephalopathy

  2001cited by this paper
• Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double‐blind, randomized, dose‐finding multi‐centre study

  2000cited by this paper
• In Vitro Activity and Fecal Concentration of Rifaximin after Oral Administration

  2000cited by this paper
• Prognostic significance of hepatic encephalopathy in patients with cirrhosis.

  1999cited by this paper
• Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.

  1998cited by this paper
• Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An italian multicenter double‐blind, placebo‐controlled, cross‐over study

  1998cited by this paper
• Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

  1997cited by this paper
• Treatment of hepatic encephalopathy.

  1997cited by this paper
• Therapeutic efficacy of L‐ornithine‐L‐aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo‐controlled, double‐blind study

  1997cited by this paper
• Severe recurrent hepatic encephalopathy that responded to oral branched chain amino acids.

  1996cited by this paper
• Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy.

  1996cited by this paper
• Neomycin reduces the intestinal production of ammonia from glutamine.

  1994cited by this paper
• [Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial].

  1994cited by this paper
• Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

  1993cited by this paper
• Rifaximin in the treatment of chronic hepatic encephalopathy.

  1993cited by this paper
• Lactitol in treatment of chronic hepatic encephalopathy

  1993cited by this paper
• Sodium benzoate in the treatment of acute hepatic encephalopathy: A double‐blind randomized trial

  1992cited by this paper
• Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy

  1992cited by this paper
• Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.

  1992cited by this paper
• Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.

  1991cited by this paper
• Rifaximine versus neomycin in the treatment of portosystemic encephalopathy.

  1991cited by this paper
• Branched chain amino acids in the management of chronic liver disease. Facts and fantasies.

  1990cited by this paper
• Effect of L-carnitine upon ammonia tolerance test in cirrhotic patients.

  1990cited by this paper
• Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis.

  1989cited by this paper
• Metronidazole pharmacokinetics in patients with hepatic encephalopathy.

  1987cited by this paper
• A non-absorbable rifamycin for treatment of hepatic encephalopathy.

  1985cited by this paper
• Rifaximin in collateral treatment of port-systemic encephalopathy: a preliminary report

  1984cited by this paper
• Comparison of Dietary Protein with an Oral, Branched Chain‐Enriched Amino Acid Supplement in Chronic Portal‐Systemic Encephalopathy: A Randomized Controlled Trial

  1984cited by this paper
• Treatment of hepatic encephalopathy with metronidazole.

  1982cited by this paper
• Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial.

  1979cited by this paper
• Drugs, alcohol and malabsorption.

  1979cited by this paper
• HYPERAMMONÆMIA, PLASMA AMINOACID IMBALANCE, AND BLOOD-BRAIN AMINOACID TRANSPORT: A UNIFIED THEORY OF PORTAL-SYSTEMIC ENCEPHALOPATHY

  1979cited by this paper
• Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy

  1978cited by this paper
• Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.

  1977cited by this paper
• Letter: Lymphocyte agglutination in multiple sclerosis.

  1975cited by this paper
• Treatment of chronic portal-systemic encephalopathy with lactulose. Report of six patients and review of the literature.

  1971cited by this paper
• Treatment of chronic portal-systemic encephalopathy with lactulose.

  1966cited by this paper

• Advances in understanding, diagnosing, and treating hepatic encephalopathy: from epidemiology to emerging therapies.

  2026cites this paper
• Encefalopatía hepática

  2024cites this paper
• Current approaches to hepatic encephalopathy.

  2022cites this paper
• Liver Failure and Hepatic Encephalopathy in Pregnancy

  2021cites this paper
• Gut Microbiome: A Potential Modifiable Risk Factor in Biliary Atresia.

  2020cites this paper
• Hepatic Encephalopathy

  2019cites this paper
• Hepatic Encephalopathy

  2019cites this paper
• The burden of clostridium difficile infection in patients with liver cirrhosis

  2019cites this paper
• Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

  2019cites this paper
• A Randomized Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy

  2019cites this paper
• ACUTE EFFECTS OF ANTIBIOTICS ON GUT MOTILITY AND GUT-BRAIN NEURONAL SIGNALLING

  2018cites this paper
• Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator‐blinded, active‐controlled trial and a phase III, multicenter, open trial

  2018cites this paper
• 16 L-carnitine in Hyperammonemia and Hepatic Encephalopathy

  2017influential citation
• Ameliorative effects of rutin on hepatic encephalopathy-induced by thioacetamide or gamma irradiation.

  2017cites this paper
• The assessment and care of patients with hepatic encephalopathy.

  2017cites this paper
• COMPARISON OF RIFAXIMIN, LACTULOSE WITH RIFAXIMIN, LACTULOSE, BRANCHED CHAIN AMINOACIDS (BCAA) IN GRADE 1 TO GRADE 3 OF HEPATIC ENCEPHALOPATHY- NON RANDOMIZED CONTROLLED TRIAL STUDY

  2017cites this paper
• Role of oral antibiotics “Neomycin vs Ciprofloxacin” for Secondary Prophylaxis of Porto-Systemic Encephalopathy in Liver Cirrhotic patients

  2016cites this paper
• Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding.

  2016cites this paper
• Hepatic encephalopathy

  2016cites this paper
• Cognition Predicts Quality of Life Among Patients With End-Stage Liver Disease.

  2016cites this paper
• Búsqueda de nuevas dianas terapéuticas en la encefalopatía hepática

  2015cites this paper
• Clostridium difficile Infection in Hospitalized Cirrhotic Patients with Hepatic Encephalopathy.

  2015cites this paper
• Nutritional assessment in cirrhotic patients with hepatic encephalopathy.

  2015cites this paper
• Chapter 36 – Monitoring and Care

  2014cites this paper
• The microbiota-gut-brain axis in functional gastrointestinal disorders

  2014cites this paper
• Branched-chain amino acid supplementation in adults with cirrhosis and porto-systemic encephalopathy: systematic review.

  2014cites this paper
• Comparative Study of Branched Chain Amino Acids Infusion with Conventional treatment in patients with Hepatic Encephalopathy due to Liver Cirrhosis

  2014cites this paper
• Protective role of antioxidants on thioacetamide-induced acute hepatic encephalopathy: biochemical and ultrastructural study.

  2013cites this paper
• Hepatic Encephalopathy: Diagnosis and Treatment Liver

  2013cites this paper
• Lack of Clostridium difficile Infection in Patients Treated With Rifaximin for Hepatic Encephalopathy: A Retrospective Analysis

  2013cites this paper
• Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study

  2013cites this paper
• Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis

  2013cites this paper
• The Future of Prebiotics and Probiotics

  2013cites this paper
• Hepatic encephalopathy.

  2012cites this paper
• Hepatic encephalopathy.

  2012cites this paper
• L-carnitine in Hyperammonemia and Hepatic Encephalopathy

  2012influential citation
• 6 Hepatic Encephalopathy

  2012cites this paper
• Management of overt hepatic encephalopathy.

  2012cites this paper
• Commensal communication to the brain: pathways and behavioral consequences

  2012cites this paper
• Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.

  2012cites this paper
• Hepatic Encephalopathy

  2012cites this paper
• rifaximin und Polyethylene Glycol as treatment Modalities in Hepatic Encephalopathy

  2012cites this paper
• Reactive astrocytes give neurons less support: implications for Alzheimer's disease.

  2012cites this paper
• Communication between gastrointestinal bacteria and the nervous system.

  2012cites this paper
• Pharmacotherapy for Hepatic encephalopathy: view of Evidence-Based Medicine

  2012cites this paper
• The metabolic and functional consequences of hyperammonaemia

  2012cites this paper
• Rifaximin und Polyethylenglykol bei hepatischer enzephalopathie

  2012cites this paper
• Microbes and the gut‐brain axis

  2012cites this paper
• Prophylaxis of hepatic encephalopathy in acute variceal bleed: A randomized controlled trial of lactulose versus no lactulose

  2011cites this paper
• Influence of Gut Microbes on the Brain-Gut Axis (Gut 2011;60:307-317)

  2011cites this paper
• 8. Hepatic Encephalopathy in Patients with Cirrhosis

  2011cites this paper
• Urinary NAG as a Biomarker of AKI in Patients with Hepatorenal Syndrome

  2011cites this paper
• Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy.

  2011cites this paper
• Effect of proinflammatory activation on the neurosupportive functions of astrocytes

  2011cites this paper
• Pharmacotherapy for Hepatic encephalopathy: view of Evidence-Based

  2011cites this paper
• The microbiota–gut–brain axis: learning from intestinal bacteria?

  2011cites this paper
• Hepatic Encephalopathy in Patients with Cirrhosis

  2011cites this paper
• Rifaximin intake leads to emergence of rifampin-resistant staphylococci.

  2011cites this paper
• Hepatic encephalopathy: from pathophysiology to therapeutic management

  2011cites this paper
• Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy.

  2011cites this paper
• Review article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement

  2011cites this paper
• Diagnostic approach to persistent hepatic encephalopathy.

  2011cites this paper
• Pharmacotherapy for Hepatic Encephalopathy

  2010cites this paper
• Review article: the modern management of hepatic encephalopathy

  2010cites this paper
• A CRITICAL EVALUATION OF THE MARS TREATMENT IN FINLAND

  2010cites this paper
• A rifaximina no tratamento da encefalopatia hepática

  2010cites this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cites this paper
• Benzoato de sodio y L-ornitina L-aspartato en ratas cirróticas hiperamonémicas

  2010cites this paper
• Hepatic Encephalopathy, Hepatorenal Syndrome, Hepatopulmonary Syndrome, and Systemic Complications of Liver Disease

  2010cites this paper
• Méthodes de traitement de maladies entériques

  2009cites this paper
• Management of Cirrhosis and Associated Complications

  2009influential citation
• Emerging Issues in Gastroenterology and Hepatology.

  2009cites this paper
• Méthodes de traitement d'une encéphalopathie hépatique

  2009cites this paper
• Verfahren zur behandlung von darmerkrankungen

  2009cites this paper
• Verfahren zur behandlung von hepatischer enzephalopathie

  2009cites this paper
• Rifaximin for Hepatic Encephalopathy

  2009cites this paper
• Local antimicrobial therapy with rifaximin : A novel perspective for irritable bowel syndrome

  2009cites this paper
• Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis

  2008cites this paper
• Probiotics and Liver Disease

  2008cites this paper
• Patient selection for liver transplant: 1-year experience with 555 patients at a single center.

  2008cites this paper
• Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy

  2007cites this paper
• Emerging Therapies for the Management of Hepatic Encephalopathy

  2007cites this paper
• An Algorithm for the Management of Hepatic Encephalopathy

  2007cites this paper
• Treatment Options for Hepatic Encephalopathy: A Review

  2007cites this paper
• Encéphalopathie hépatique : comment optimiser la prise en charge en réanimation ?

  2007cites this paper
• An algorithm for the management of hepatic encephalopathy

  2007cites this paper